The firms will use MGI's sequencing technology and Curetis' sample prep platform and antibiotic resistance database to develop IVDs, initially for China.
Ares plans to use the GEAR database to discover new markers of antibiotic resistance and will eventually develop it as an interpretation service.
Among other plans, CosmosID is using the funds to prep its platform for clinical use including running validation studies with partner hospitals.
Researchers generated a near complete genome sequence for a 5,300 year old Helicobacter pylori strain found in the gut of Ötzi, the Tyrolean Iceman.
The researchers demonstrated that the panel could identify pathogens in mock clinical samples even at very low levels, while unbiased sequencing could not.
The Toronto-based firm will use the funds to finance ongoing molecular diagnostics product development and expansion.
The Virginia-based firm will use the funds to build out its next-generation sequencing data analytics for pathogen identification and surveillance.
The funding comes as part of the agency's Advanced Molecular Detection initiative, which is using the technologies to help address infectious disease outbreaks.
The initiative aims to integrate clinical, genomic, environmental, and other data from patients to help determine disease mechanisms and develop precise therapies.
The firm plans to begin offering a cloud-based version of its software as well as a possible appliance by the end of the summer.
Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.
The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.
In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.
China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.